Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumours: Preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts

• Published in: Annals of oncology Vol. 30; p. v494
• Main Authors: Conter, H.J., MacDonald, L.D., Fiset, S., Bramhecha, Y.M., Chaney, M., Rosu, G.N.
• Format: Journal Article
• Language: English
• Published: 01.10.2019